Off-Label Dermatologic Uses of Anti-TNF-a Therapies
- 1 December 2005
- journal article
- research article
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
- Vol. 9 (6) , 296-302
- https://doi.org/10.1007/s10227-005-0110-7
Abstract
Tumor necrosis factor-alpha (TNF-a) is a proinflammatory cytokine that plays an immunomodulatory role in a variety of systemic and dermatologic diseases. Currently, three anti-TNF-a drugs are available in North America— infliximab (approved in the U.S. for the treatment of rheumatoid arthritis, Crohn’s disease, ankylosing spondylitis, ulcerative colitis, and psoriatic arthritis), etanercept (approved in the U.S. for the treatment of rheumatoid arthritis, juvenile rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and psoriasis), and adalimumab (approved for the treatment of rheumatoid arthritis and psoriatic arthritis).Keywords
This publication has 55 references indexed in Scilit:
- Safety of Tumour Necrosis Factor-?? AntagonistsDrug Safety, 2004
- Use of Infliximab, an Anti-Tumor Necrosis Alpha Antibody, for Inflammatory DermatosesJournal of Cutaneous Medicine and Surgery, 2003
- Etanercept: An overviewJournal of the American Academy of Dermatology, 2003
- Etanercept for the Treatment of Stage II and III Progressive Pulmonary SarcoidosisChest, 2003
- Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn’s diseaseGastroenterology, 2003
- SarcoidosisThe Lancet, 2003
- Progressive cutaneous sarcoidosis responding to anti-tumor necrosis factor-? therapyJournal of the American Academy of Dermatology, 2003
- Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing AgentNew England Journal of Medicine, 2001
- Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trialThe Lancet, 2001
- SarcoidosisNew England Journal of Medicine, 1997